Eli Lilly Performs Better Than Expected In Q411 Despite Revenue Drop

BMI View: Despite the revenue decrease in Q411 due to the expiration of Zyprexa (olanzapine)'s patent protection, Eli Lilly's attractiveness to investors is increasing, albeit from a low base, due to its robust new product performance and partnerships with other companies. It is our view that Eli Lilly should focus more on emerging market expansion to offset the negative effects of US healthcare reform and the loss of patent protection of its

To read the full article, please choose one of the following options: